Understand the source comparison
Best Peptides for Neuropathic Pain: Research Comparison
This table compares the five peptides with the strongest preclinical and clinical evidence for neuropathic pain relief based on mechanism, onset, and research-demonstrated efficacy. BPC-157 VEGF upregulation, nitric oxide signaling, nerve regeneration 7–14 day
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the five peptides with the strongest preclinical and clinical evidence for neuropathic pain relief based on mechanism, onset, and research-demonstrated efficacy.
- BPC-157
- VEGF upregulation, nitric oxide signaling, nerve regeneration
- 7–14 days
- 40–60% reduction in tactile allodynia (diabetic neuropathy models)
- Best for peripheral neuropathy with vascular compromise. Diabetic, ischemic, or compression-related
- Cerebrolysin
- BDNF/CNTF mimetic, NMDA receptor modulation, synaptic protection
- 14–21 days
- 52% reduction in hyperalgesia (chemotherapy-induced neuropathy)
- Best for chemotherapy-induced or post-stroke central pain. Crosses blood-brain barrier
- Thymulin
- Immune modulation, T-cell balance restoration, cytokine suppression
- 14–28 days
- 47% reduction in allodynia (autoimmune neuritis models)
- Best for autoimmune-mediated demyelination. Guillain-Barré, CIDP, or MS-related pain
- Dihexa
- HGF/Met receptor agonism, synaptogenesis, dendritic remodeling
- 10–14 days
- 65% improvement in mechanical thresholds (spinal cord injury models)
- Best for central sensitization. Spinal injury, thalamic stroke, or refractory central pain
- KPV
- NF-κB inhibition, anti-inflammatory, oxidative stress reduction
- 7–10 days
- 60% reduction in pro-inflammatory cytokines (neuroinflammation models)
- Best for acute inflammatory neuropathies. Post-surgical nerve injury or viral neuritis